Previous 10 | Next 10 |
2024-01-04 07:21:44 ET More on ADC Therapeutics ADC Therapeutics: Rising From The Ashes Of A Halted Drug Trial ADC Therapeutics: Navigating A Swirling Drain ADC Therapeutics SA (ADCT) Q3 2023 Earnings Call Transcript ADC Therapeutics rises after promising ear...
LAUSANNE, Switzerland, Jan. 04, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it received a notice from the New York Stock Exchange (NYSE) on January 2, 2024 that the Company has regained compliance with the continued listing minimum price criteria set forth in Se...
ZYNLONTA ® 1 4Q 2023 net sales expected to be ~$16.5 million, a double-digit percentage increase as compared to 3Q 2023 LOTIS-7: Study of ZYNLONTA in combination with bispecifics cleared first dosing cohort with no DLT and with early signs of efficacy ...
2024-01-02 10:00:09 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Covid-vaccine makers top laggard list, LLY and WST top gainers list Healthcare and uti...
2023-12-29 14:20:49 ET Summary ADCs are a promising development in cancer treatment, targeting specific tumors with minimal side effects. ADCT's first drug, Zynlonta, was approved for third line treatment of lymphoma, but a halted trial for second line treatment was a setback. ...
2023-12-13 18:29:59 ET DENVER, Colo., Dec. 13, 2023 ( www.247marketnews.com )- 24/7 Market News covered the following companies today; Shattuck Labs Inc (NASDAQ: STTK), Reshape Lifesciences Inc (NASDAQ: RSLS), C4 Therapeutics Inc. (NASDAQ: CCCC), Chanson International Holding (NASDAQ: C...
2023-12-13 12:26:11 ET DENVER, Colo., Dec. 13, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Shattuck Labs Inc (NASDAQ: STTK), Reshape Lifesciences Inc (NASDAQ: RSLS), SciSparc Ltd (NASDAQ: SPRC)...
2023-12-12 07:56:00 ET C4 Therapeutics ( CCCC ) +72% stock rallies on Merck deal to develop cancer antibodies. Icosavax ( ICVX ) +47% to acquire vaccine maker Icosavax in ~$1.1B deal. IN8bio ( INAB ) +24% . Clean Earth Acquisitions ( ...
2023-12-12 06:11:01 ET ADC Therapeutics ( NYSE: ADCT ) shares jumped 13% premarket on Tuesday after reporting encouraging early results for a combination therapy for patients with relapsed/refractory follicular lymphoma (FL). In an investigator-initiated Phase 2 clinical...
Combination demonstrated clinically meaningful benefit in r/r FL patients with 96% overall response rate and 85% complete response rate LAUSANNE, Switzerland, Dec. 12, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced initial results from an investigator-initiated Ph...
News, Short Squeeze, Breakout and More Instantly...
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and Abingworth Additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova Partners Funds will be used to ...
LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company is set to join the Russell 2000 ® Index and the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, ef...